Drug overpricing: Govt plans amnesty scheme to recover dues from pharma companies

In a bid to tackle overpricing in the pharmaceutical sector, the government is planning an amnesty scheme to recover dues from pharmaceutical companies, CNBC Aawaz reported.

The National Pharmaceutical Pricing Authority (NPPA), responsible for overseeing drug pricing, has identified a substantial 2,200 cases of overpricing within the pharmaceutical industry.

Among the companies under scrutiny for overpricing practices are well-known names such as Cipla, Sun Pharma, and Lupin. These cases collectively involve dues amounting to approximately Rs. 13,000 crore.

The amnesty scheme proposes relief for pharmaceutical companies, offering waivers on interest and penalties associated with the alleged overpricing issues.

Pharma makers get a year for GMP implementation, Mandaviya warns action on defaults

The primary objective of the amnesty scheme is to recover outstanding dues from these companies. It is estimated that the government aims to retrieve around Rs. 5,000 to 6,000 crore through this initiative.

How are drug prices regulated?

Periodically, the Health Ministry collaborates with experts to create the National List of Essential Medicines (NLEM). This list includes medications vital for treating prevalent conditions and falls under price control through the Drug Price Control Order (DPCO).

The NPPA, a part of the Indian Government, was established to regulate drug prices. It enforces pricing and availability of medicines as per the Drugs (Prices Control) Order, 1995. NPPA also recovers overcharged amounts from consumers and monitors prices of unregulated drugs to ensure affordability.

Related Posts

Unapproved drops for dry eyes pose risks: Govt

NEW DELHI: Flagging that certain yet-to-be-approved dry eye relief drops are being sold in the market, the central drugs regulator has asked states to cancel any permissions granted for these…

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Unapproved drops for dry eyes pose risks: Govt

Unapproved drops for dry eyes pose risks: Govt

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

Govt highlights multi-layer framework to curb misleading advertisements

Govt highlights multi-layer framework to curb misleading advertisements

Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

Study finds rising resistance to a last-resort antibiotic in Africa

Study finds rising resistance to a last-resort antibiotic in Africa